Novo Nordisk shares jump 6% on FDA move to limit weight-loss drug compounding

Investing.com Gold reports: Novo Nordisk shares jump 6% on FDA move to limit weight-loss drug compounding. Full body text was unavailable at ingest time, so this brief is based on headline context.